CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type
lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary
efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid
leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is
no longer responding to other treatment (refractory). Participants must have received at
least 1 but not more than 3 prior lines of treatment for AML .